免疫检查点抑制剂与靶向治疗对III期和IV期黑色素瘤患者健康相关生活质量的影响:一项混合方法系统评价
该混合方法系统评价纳入28篇文献(27项研究),评估免疫检查点抑制剂(ICI)与靶向治疗(TT)对III期和IV期皮肤黑色素瘤患者健康相关生活质量(HRQL)的影响。在已切除III期患者中,辅助帕博利珠单抗与达拉非尼-曲美替尼未较基线临床或统计学改变HRQL;在不可切除III/IV期患者中,ICI对症状、功能和整体HRQL的影响在不同研究设计间不一致,而TT在六项研究中与症状、功能和HRQL改善相关。
要点
- 已切除III期黑色素瘤辅助帕博利珠单抗或达拉非尼-曲美替尼未较基线临床或统计学改变HRQL。
- 不可切除III/IV期黑色素瘤中,ICI对症状、功能和整体HRQL的影响在不同研究设计间不一致。
- 靶向治疗在六项研究中与不可切除III/IV期黑色素瘤患者症状、功能和HRQL改善相关。
核心结论
- 本综述强调III期和IV期黑色素瘤患者在接受ICI和TT时经历的关键躯体、心理和社会问题。
- 不同研究设计中观察到ICI对HRQL影响的不一致性。
- 这凸显需要治疗特异性患者报告结局测量工具来判定这些疗法对HRQL的影响,并需要真实世界数据以支持治疗决策和适当的支持性护理干预。
研究设计与样本
- 混合方法系统评价,于2022年4月在MEDLINE、PsycINFO、Embase和Cochrane中央对照试验注册库进行系统文献检索。
- 纳入28篇文献描述27项研究:15项随机对照试验、4项队列研究、4项单臂横断面研究、2项定性研究、1项病例对照研究和1项混合方法研究。
- 定量与定性数据按设置(辅助治疗对比转移性)、治疗类型(ICI对比TT)和HRQL问题提取并汇总于表格。
主要发现
- 在4项已切除III期黑色素瘤研究中,辅助帕博利珠单抗和达拉非尼-曲美替尼未较基线临床或统计学改变HRQL。
- 在17项不可切除III/IV期黑色素瘤研究中,ICI对症状、功能和整体HRQL的影响在不同研究设计间不一致。
- 靶向治疗在6项研究中与症状、功能和HRQL改善相关。
局限性
- 不同研究设计中观察到ICI对HRQL影响的不一致性。
- 需要治疗特异性患者报告结局测量工具和真实世界数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICI) and targeted therapies (TT) have significantly improved disease control and survival in people with stage III and IV cutaneous melanoma. Understanding the impact of therapy on health-related quality of life (HRQL) is vital for treatment decision-making and determining targets for supportive care intervention. We conducted a mixed-methods systematic review to synthesise the impact of ICIs and TT on all domains of HRQL in these populations. METHODS: A systematic literature search was conducted in April 2022 on MEDLINE, PsycINFO, Embase and the Cochrane Central Register of Controlled Trials. Quantitative and qualitative data relevant to the review question were extracted and synthesised in tables according to setting (adjuvant versus metastatic), treatment type (ICI versus TT) and HRQL issue. RESULTS: Twenty-eight papers describing 27 studies were included: 15 randomised controlled trials (RCTs), four cohort studies, four single arm cross-sectional studies, two qualitative studies, one case control study and one mixed-methods study. In four studies of people with resected stage III melanoma, adjuvant pembrolizumab and dabrafenib-trametinib did not clinically or statistically change HRQL compared to baseline. In 17 studies of people with unresectable stage III/IV melanoma, inconsistencies in the impact of ICI on symptoms, functioning and overall HRQL were noted across different study designs. TT was associated with improvements in symptoms, functioning and HRQL across six studies. CONCLUSION: This review highlights the key physical, psychological and social issues experienced by people with stage III and IV melanoma treated with ICI and TT. Inconsistencies in the impact of ICI on HRQL were observed in different study designs. This highlights the need for treatment-specific patient-reported outcome measures for determining the impact of these therapies on HRQL and real-world data to inform treatment decision-making and appropriate supportive care interventions.
引用
- Lai-Kwon J, Inderjeeth AJ, Lisy K, et al. Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review. Eur J Cancer. 2023. PMID: 36907021. doi:10.1016/j.ejca.2023.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。